Check if two breast cancer treatments work better after surgery
Treatments studied
Part of Cancer clinical trials.
This trial compares two treatment approaches in people with high-risk hormone-positive, HER2-negative breast cancer that has spread to certain lymph nodes. It looks at which option works best to lower cancer returning and to control the disease after surgery and initial chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman age 18–70
- Your breast cancer can be removed with surgery, and no visible tumor remains after surgery
- You have hormone-receptor positive and HER2-negative breast cancer, with cancer in at least 4 lymph nodes on the same side
- There is no sign of spread to distant organs (no metastasis) on pre-surgery scans
- You can start the trial’s usual chemotherapy within 8 weeks after surgery and you are well enough to continue (recovery and activity score 0–1)
- Your blood counts, liver/kidney tests, heart pumping strength, and overall organ health are adequate
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 trial compares two post-surgery drug plans for HER2-positive early breast cancer that has spread to nearby lymph nodes. It may help reduce cancer recurrence by testing which regimen works better after surgery.
This trial tests a combination of two drugs, trastuzumab deruxtecan (SHR-A1811) and pertuzumab, given before surgery to shrink HER2-positive breast cancer. It is for women with stage II or III breast cancer who have not yet had treatment and are in good overall health.
This study is comparing two different drug combinations given before breast cancer surgery. The goal is to see which one shrinks tumors more effectively. This type of treatment is called 'neoadjuvant' therapy.
This trial tests a combination of two drugs (KN026 and HB1801) given after surgery to prevent breast cancer from coming back in people with HER2-positive breast cancer that had spread to lymph nodes. It aims to improve cure rates with a targeted approach.
This trial studies a faster, higher-frequency chemotherapy schedule given before surgery for HER2-negative breast cancer. It aims to see if this approach works better and is safe for the patient’s cancer stage.
This trial tests two different combinations of chemotherapy and targeted therapy given before surgery for HER2-positive breast cancer. The goal is to see which combination works better at shrinking the tumor.
Hear when a new Hormone Receptor Positive HER-2 Negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.